Fractyl Health 'encouraged' by results from diabetes reversal study – Mass Device

MassDevice
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
January 31, 2023 By Sean Whooley
Fractyl Health announced today that six-month data from a study of its diabetes reversal tech demonstrated improvements in glucose control.
Interim data came from the human clinical experience in Fractyl’s Revita-T2Di long-term, open-label cohort. Revita, a procedure that remodels the duodenal lining via hydrothermal ablation, has FDA breakthrough device designation. The FDA approved an investigational device exemption (IDE) trial for Revita in April 2022.
Lexington, Massachusetts-based Fractyl aims for Revita to improve glycemic control and eliminate insulin needs in type 2 diabetes patients. These patients currently suffer from inadequate control on long-acting insulin. Interim data not only showed improved glycemic control but also stronger metabolic control and reduced insulin requirement.
Get the full story at our sister site, Drug Delivery Business News.
Filed Under: Clinical Trials, Diabetes Tagged With: Fractyl Health
Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor’s degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.
Copyright © 2023 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.
Advertise | Privacy Policy

source